Search

Displaying results 8141 - 8150 of 10000 in total
  1. Drug

    GlycoPEG-GCSF

    go.drugbank.com/drugs/DB06022
    Experimental

    GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

  2. Drug

    Antilymphocyte immunoglobulin (horse)

    go.drugbank.com/drugs/DB09312
    ApprovedInvestigational

    It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. … The result is polyclonal IgG that is then purified from the horse's serum to produce a usable drug product that can be used for immunosuppression.

  3. Drug

    GnRH pharmaccine

    go.drugbank.com/drugs/DB05815
    Experimental

    The GnRH pharmaccine consists of synthetic peptides (constructed to "look like" GnRH), which are bound chemically to a carrier and suspended in a proprietary "delivery vehicle". … The pharmaccine is administered intramuscularly to the patient by injection and induces an immune response or production of antibodies in the patient, which neutralize GnRH thus removing it from circulation

  4. Drug

    Amuvatinib

    go.drugbank.com/drugs/DB12742
    Investigational

    Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells. … Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3.

    Synonyms: 1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro(3,2-d)pyrimidin-4-yl-, 4-[1]Benzofuro[3,2-D]Pyrimidin-4-Yl-N-(1,3-Benzodioxol-5-Ylmethyl)Piperazine-1-Carbothioamide
  5. Drug

    Xanthine

    go.drugbank.com/drugs/DB02134
    Investigational

    A purine base found in most body tissues and fluids, certain plants, and some urinary calculi. … It is an intermediate in the degradation of adenosine monophosphate to uric acid, being formed by oxidation of hypoxanthine.

  6. Drug

    PI-0824

    go.drugbank.com/drugs/DB05516
    Investigational

    Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824. … Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide.

  7. Drug

    D2C7 immunotoxin

    go.drugbank.com/drugs/DB17540
    Investigational

    D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL.

  8. Drug

    Farletuzumab ecteribulin

    go.drugbank.com/drugs/DB18857
    Investigational

    Farletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), … a Folate Receptor Alpha (Frα)-targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types).

  9. Drug

    5-(5-(4-(4,5-dihydro-2-oxazoly)phenoxy)pentyl)-3-methyl osoxazole

    go.drugbank.com/drugs/DB08720
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. This drug is known to target genome polyprotein. … 5-(5-(4-(4,5-dihydro-2-oxazoly)phenoxy)pentyl)-3-methyl osoxazole is a solid. This compound belongs to the phenol ethers.

  10. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    SAR445136 is an investigational zinc finger nuclease gene-edited cell therapy.